Skip to main content

Company Update: Actavis plc (NYSE:ACT) – Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer’s Disease

[PR Newswire] – DUBLIN, Ireland, May 18, 2015 /PRNewswire/ — Actavis plc (NYSE: ACT) today announced that NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a once-daily, fixed-dose combination … Read more on this. . . . → Read More: Company Update: Actavis plc (NYSE:ACT) – Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer’s Disease Similar Articles: Stock Update (NYSE:ACT): Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30 Company Update (NYSE:ACT): (OFFICIAL)-UPDATE 1-Actavis’ superbug antibiotic gets U.S. approval (Feb. 25) Stock Update (NYSE:PFE): Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.